The Future of Vaccine Discovery and Development

  • Adel Mahmoud


The science and practice of vaccination were initially based on multiple historical observations that related the acquisition of protection against a specific microbe to a previous exposure to the same agent (Hilleman 2003). Although, in modern history, the practice was confined to inducing protection against infectious diseases, its historical roots extended to exposures to toxins, and its current conceptual framework encompasses many more pathological conditions, such as cancer (Finn 2008). Fundamentally, vaccination aims at inducing host immune responses to mount preventive or therapeutic defenses against diseases of varying etiologies, including those of infectious, and potentially autoimmune or neoplastic origin. This chapter defines our current understanding of the challenges facing the discovery and development of new vaccines for a variety of disease conditions; the aim is to identify the critical steps in exploring future imperatives and directions.


Smallpox Vaccine Recombinant HBsAg Vaccine Discovery Immunogen Identification Protective Immunogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455(7213):613–619CrossRefPubMedGoogle Scholar
  2. Blumberg BS (1997) Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci USA 94(14):7121–7125CrossRefPubMedGoogle Scholar
  3. Bochner BR (2009) Global phenotypic characterization of bacteria. FEMS Microbiol Rev 33(1):191–205CrossRefPubMedGoogle Scholar
  4. Chen XS, Garcea RL, Goldberg I et al (2000) Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5(3):557–567CrossRefPubMedGoogle Scholar
  5. Dethlefsen L, McFall-Ngai M, Relman DA (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449(7164):811–818CrossRefPubMedGoogle Scholar
  6. Durst M, Gissmann L, Ikenberg H et al (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80(12):3812–3815CrossRefPubMedGoogle Scholar
  7. Dyson N, Howley PM, Munger K et al (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243(4893):934–937CrossRefPubMedGoogle Scholar
  8. Fauci AS, Johnston MI, Dieffenbach CW et al (2008) HIV vaccine research: the way forward. Science 321(5888):530–532CrossRefPubMedGoogle Scholar
  9. Finn OJ (2008) Cancer immunology. N Engl J Med 358(25):2704–2715CrossRefPubMedGoogle Scholar
  10. Garcia-Hernandez Mde L, Gray A, Hubby B et al (2008) Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68(3):861–869CrossRefPubMedGoogle Scholar
  11. Heaton PM, Ciarlet M (2007) Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin Infect Dis 45(12):1618–1624CrossRefPubMedGoogle Scholar
  12. Hilleman M (2003) Overview of vaccinology in historic and future perspective: The whence and whithers of a dynamic sequence with complex dimensions. In: Hildegend C (ed) DNA vaccines. Academic/Plennum Publishers, New YorkGoogle Scholar
  13. Inoges S, Rodriguez-Calvillo M, Zabalegui N et al (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98(18):1292–1301CrossRefPubMedGoogle Scholar
  14. Ji H, Houghton AM, Mariani TJ et al (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene 25(14):2105–2112CrossRefPubMedGoogle Scholar
  15. Kirnbauer R, Booy F, Cheng N et al (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89(24):12180–12184CrossRefPubMedGoogle Scholar
  16. Lederberg J (2000) Infectious history. Science 288(5464):287–293CrossRefPubMedGoogle Scholar
  17. Lowy DR, Schiller JT (2006) Prophylactic human papillomavirus vaccines. J Clin Invest 116(5):1167–1173CrossRefPubMedGoogle Scholar
  18. Mach H, Volkin DB, Troutman RD et al (2006) Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 95(10):2195–2206CrossRefPubMedGoogle Scholar
  19. Mahmoud A (2007) The march of HIV vaccines. Science 316(5828):1123–1124CrossRefPubMedGoogle Scholar
  20. Mahmoud A, Levin M (2007) Vaccines at the turn of the 21st century: a new era for immunization in public health. Int J Infect Dis 11(Suppl 2):S1–2CrossRefPubMedGoogle Scholar
  21. Mendelsohn J (1997) Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3(12 Pt 2):2703–2707PubMedGoogle Scholar
  22. Mettens P, Dubois PM, Demoitie MA et al (2008) Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 26(8):1072–1082PubMedGoogle Scholar
  23. Mukherjee S, Thorsteinsson MV, Johnston LB et al (2008) A quantitative description of in vitro assembly of human papillomavirus 16 virus-like particles. J Mol Biol 381(1):229–237CrossRefPubMedGoogle Scholar
  24. Plotkin SA (2005) Vaccines: past, present and future. Nat Med 11(4 Suppl):S5–11CrossRefPubMedGoogle Scholar
  25. Pulendran B (2007) Tolls and beyond – many roads to vaccine immunity. N Engl J Med 356(17):1776–1778CrossRefPubMedGoogle Scholar
  26. Reed SG, Bertholet S, Coler RN et al (2008) New horizons in adjuvants for vaccine development. Trends Immunol 30(1):23–32CrossRefPubMedGoogle Scholar
  27. Rocha EP (2008) The organization of the bacterial genome. Annu Rev Genet 42:211–233CrossRefPubMedGoogle Scholar
  28. Roy P, Noad R (2008) Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 4(1):5–12PubMedGoogle Scholar
  29. Scheffner M, Werness BA, Huibregtse JM et al (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6):1129–1136CrossRefPubMedGoogle Scholar
  30. Turnbaugh PJ, Gordon JI (2008) An invitation to the marriage of metagenomics and metabolomics. Cell 134(5):708–713CrossRefPubMedGoogle Scholar
  31. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320(5877):760–764CrossRefPubMedGoogle Scholar
  32. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248(4951):76–79CrossRefPubMedGoogle Scholar
  33. Yamaguchi M, Sugahara K, Shiosaki K et al (1998) Fine structure of hepatitis B virus surface antigen produced by recombinant yeast: Comparison with HBsAg of human origin. FEMS Microbiol Lett 165(2):363–367CrossRefPubMedGoogle Scholar
  34. Zhao Q, Wang Y, Freed D et al (2006) Maturation of recombinant hepatitis B virus surface antigen particles. Hum Vaccin 2(4):174–180PubMedGoogle Scholar
  35. Zhou J, Sun XY, Stenzel DJ et al (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185(1):251–257CrossRefPubMedGoogle Scholar
  36. zur Hausen H (2008) Papillomaviruses - to vaccination and beyond. Biochemistry 73:498–503PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Molecular Biology and Woodrow Wilson School of Public and International AffairsPrinceton UniversityPrincetonUSA

Personalised recommendations